HONG KONG – You win some and you lose some. Fresh from losing a licensing deal with German pharmaceutical giant Boehringer Ingelheim GmbH and watching its stock price plummet, South Korea’s Hanmi Pharmaceutical Co. Ltd. inked an exclusive $910 million development and licensing agreement with Genentech Inc., of South San Francisco, for the development and commercialization of its pan-RAF inhibitor, HM95573.
